Early research (Phase 1)Ended earlyNCT03746431What this trial is testing[225Ac]-FPI-1434 InjectionWho this might be right forAdvanced Solid TumoursEndometrial CancerCervical Cancer+7 more Fusion Pharmaceuticals Inc. 78
Early research (Phase 1)Study completedNCT04881045What this trial is testingStudy to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.Who this might be right forNon-Small Cell Lung CancerSquamous Cell Carcinoma of the Head and NeckOvarian Cancer Pfizer 29
Large-scale testing (Phase 3)Not Yet RecruitingNCT07758621What this trial is testingSYS6010 vs Investigator's Choice of Monotherapy in Patients With Recurrent or Metastatic HNSCCWho this might be right forHead and Neck Squamous Cell Carcinoma CSPC Megalith Biopharmaceutical Co.,Ltd. 340
Testing effectiveness (Phase 2)Looking for participantsNCT07554521What this trial is testingEvaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United StatesWho this might be right forAdvanced Unresectable Gastric AdenocarcinomaEsophageal Squamous Cell CarcinomaAdvanced Gastroesophageal Adenocarcinoma BeOne Medicines 30
Early research (Phase 1)Looking for participantsNCT06999187What this trial is testingDR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory CarcinomasWho this might be right forTriple Negative Breast CancerHER2-negative Breast CancerNon Small Cell Lung Cancer+9 more Dren Bio 96
Testing effectiveness (Phase 2)Study completedNCT00016900What this trial is testingPNU-93914 in Treating Patients With Locally Advanced or Metastatic Cancer of the EsophagusWho this might be right forEsophageal Cancer Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT07105592What this trial is testingNimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell CarcinomaWho this might be right forHead and Neck Squamous Cell Carcinoma Fudan University 68
Early research (Phase 1)Ended earlyNCT05061537What this trial is testingStudy of PF-07263689 in Participants With Selected Advanced Solid TumorsWho this might be right forRenal Cell CancerMelanomaNon-Small-Cell Lung Cancer+7 more Pfizer 13
Testing effectiveness (Phase 2)Ended earlyNCT06046482What this trial is testingPhase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell CarcinomaWho this might be right forHead NeckSquamous Cell Carcinoma of Head and Neck M.D. Anderson Cancer Center 4
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07662720What this trial is testingA Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck CancerWho this might be right forHead and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M) Glycyx Therapeutics 18
Testing effectiveness (Phase 2)Ended earlyNCT03258008What this trial is testingUtomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal CancerWho this might be right forMalignant Neoplasms of Ill-defined Secondary and Unspecified SitesMalignant Neoplasms of Lip Oral Cavity and PharynxOropharyngeal Cancer M.D. Anderson Cancer Center 3
Large-scale testing (Phase 3)UnknownNCT03958890What this trial is testingA Clinical Trial Comparing HLX10 With Placebo Combined With Chemotherapy (Cisplatin + 5-fu) in the First-line Treatment of Locally Advanced/Metastatic Esophageal Squamous Cell Carcinoma (ESCC)Who this might be right forEsophageal Squamous Cell Carcinoma Shanghai Henlius Biotech 489
Testing effectiveness (Phase 2)UnknownNCT04398524What this trial is testingA Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPCWho this might be right forSquamous Cell Carcinoma of the Oropharynx ISA Pharmaceuticals 65
Early research (Phase 1)Study completedNCT00010023What this trial is testingCapecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid TumorsWho this might be right forCancer NYU Langone Health
Large-scale testing (Phase 3)Active Not RecruitingNCT05078047What this trial is testingStudy Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IOWho this might be right forLung Cancer MetastaticRenal Cell CarcinomaHead and Neck Cancer+12 more UNICANCER 646
Testing effectiveness (Phase 2)UnknownNCT04650633What this trial is testingSHR-1701 in Patients With Recurrent/Metastatic ScchnWho this might be right forSquamous Cell Carcinoma of Head and Neck Jiangsu HengRui Medicine Co., Ltd. 130
Testing effectiveness (Phase 2)Looking for participantsNCT06747585What this trial is testingInvestigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid TumorsWho this might be right forSquamous Non-small-cell Lung CancerHead and Neck Squamous Cell CarcinomaCervical Squamous Cell Carcinoma+1 more Alentis Therapeutics AG 170
Early research (Phase 1)Study completedNCT06236425What this trial is testingTBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCCWho this might be right forSquamous Cell Carcinoma of Head and NeckMetastatic Squamous Cell Carcinoma H. Lee Moffitt Cancer Center and Research Institute 7
Testing effectiveness (Phase 2)Study completedNCT00268671What this trial is testingDocetaxel in Squamous Cell Carcinoma of the Head and Neck (TAX + Cisplatin in SCCHN)Who this might be right forHead and Neck Neoplasms Sanofi 45
Early research (Phase 1)Ended earlyNCT00906360What this trial is testingSunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and NeckWho this might be right forMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell CarcinomaRecurrent Metastatic Squamous Neck Cancer With Occult PrimaryRecurrent Salivary Gland Cancer+29 more National Cancer Institute (NCI) 36